Definium Therapeutics (DFTX) Financials
Ticker history: MNMD became DFTX (Definium Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View MNMD history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DFTX SEC filings page.
This page shows Definium Therapeutics, Inc. (DFTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Definium is funding an intensifying development program through external capital while operating losses and cash use continue to widen.
R&D reached$117.7M after rising80.2% , while operating cash outflow expanded from$79.1M in FY2024 to$131.6M in FY2025. That combination indicates development spending is increasing the near-term cash requirement rather than being funded by operating activity.
R&D rose
Financing cash inflow of
Financial Health Signals
We do not publish a peer-relative financial health score for Definium Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Definium Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Definium Therapeutics, Inc. reported a net loss of $183.8M while operations used $131.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Definium Therapeutics, Inc. reported an operating loss of $166.3M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Definium Therapeutics, Inc. reported a net loss of $51.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Definium Therapeutics, Inc. earned -$0.46 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Definium Therapeutics, Inc. held $241.2M in cash against $36.7M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Definium Therapeutics, Inc.'s quarterly ROE was -5.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 46.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.0 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Definium Therapeutics, Inc. invested $46.1M in research and development in Q3 2026. This represents an increase of 48.9% from the same quarter a year earlier. Against the prior quarter it is down 5.2%.
Not reported for Q3 2026.
Not reported for Q3 2026.
DFTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $46.1M+48.9% | $48.7M+63.3% | $41.5M+77.6% | $33.5M+54.1% | $31.0M+80.2% | $29.8M+103.5% | $23.4M+99.5% | $21.8M+88.5% |
| SG&A Expenses | $26.1M+77.9% | $26.4M+138.1% | $17.7M+101.5% | $14.1M+31.3% | $14.7M+93.2% | $11.1M+13.1% | $8.8M-16.2% | $10.7M+0.4% |
| Operating Income | -$72.3Mn/m | -$75.1Mn/m | -$59.2Mn/m | -$47.6Mn/m | -$45.7Mn/m | -$40.9Mn/m | -$32.2Mn/m | -$32.5Mn/m |
| Interest Expense | $1.1M-9.7% | $1.2M-47.3% | $1.2M+106.8% | N/A | $1.3M+75.2% | $2.3M+401.7% | $602K+38.7% | N/A |
| Net Income | -$51.0Mn/m | -$159.0Mn/m | -$77.1Mn/m | -$50.4Mn/m | -$67.3Mn/m | -$42.7Mn/m | -$23.3Mn/m | -$34.7Mn/m |
| EPS (Basic) | -$0.37n/m | -$1.44n/m | -$0.71 | -$0.50n/m | -$0.78 | -$0.50 | -$0.27 | -$0.42 |
| EPS (Diluted) | -$0.46n/m | -$1.44n/m | -$0.71 | -$0.50n/m | -$0.78 | -$0.50 | -$0.35 | -$0.42 |
| Diluted Shares (Avg) | 137M+59.9% | 111M+29.7% | 109M | N/A | 86M | 85M | 87M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
DFTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B+353.4% | $1.1B+319.8% | $401.3M+45.8% | $440.1M+45.7% | $236.9M-25.9% | $265.1M-1.1% | $275.3M-0.1% | $302.2M+142.6% |
| Current Assets | $1.1B+387.3% | $1.1B+477.4% | $380.6M+71.7% | $419.3M+48.9% | $215.8M-27.9% | $189.1M-23.6% | $221.7M-13.2% | $281.6M+171.1% |
| Cash & Equivalents | $241.2M+1108.2% | $655.3M+1862.3% | $262.5M+216.8% | $257.8M-5.8% | $20.0M-93.2% | $33.4M-86.3% | $82.9M-67.2% | $273.7M+174.6% |
| Short-Term Investments | $805.7M+326.0% | $428.6M+186.5% | $110.9M-14.4% | $153.8Mn/m | $189.1Mn/m | $149.6Mn/m | $129.6Mn/m | $0n/m |
| Long-Term Investments | $0n/m | $0-100.0% | $0-100.0% | $0n/m | $0n/m | $54.9Mn/m | $33.1Mn/m | $0n/m |
| Goodwill | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% | $19.9M0.0% |
| Total Liabilities | $106.2M-0.1% | $194.2M+143.7% | $122.4M+133.2% | $107.8M+77.5% | $106.3M+84.7% | $79.7M+20.6% | $52.5M-33.9% | $60.7M+30.8% |
| Current Liabilities | $67.7M+3.5% | $157.2M+314.2% | $81.1M+166.1% | $66.7M+71.7% | $65.4M+96.7% | $38.0M-9.3% | $30.5M-53.3% | $38.8M+20.5% |
| Non-Current Liabilities | $38.5M-5.8% | $37.0M-11.3% | $41.3M+87.6% | $41.1M+88.0% | $40.9M+68.3% | $41.7M+72.1% | $22.0M+55.1% | $21.9M+54.3% |
| Long-Term Debt | $36.7M-9.2% | $36.5M-11.5% | $40.8M+85.0% | $40.6M+85.7% | $40.4M+66.1% | $41.2M+69.9% | $22.0M+55.3% | $21.9M+54.7% |
| Total Equity | $968.0M+641.2% | $918.7M+395.5% | $278.8M+25.2% | $332.3M+37.6% | $130.6M-50.2% | $185.4M-8.2% | $222.8M+13.6% | $241.4M+209.0% |
| Retained Earnings | -$869.7Mn/m | -$818.8Mn/m | -$659.8Mn/m | -$582.7Mn/m | -$532.2Mn/m | -$465.0Mn/m | -$422.2Mn/m | -$398.9Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable.
DFTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$53.0Mn/m | -$52.8Mn/m | -$42.6Mn/m | -$43.0Mn/m | -$29.6Mn/m | -$29.6Mn/m | -$29.4Mn/m | -$25.4Mn/m |
| Stock-Based Compensation | $10.8M+85.3% | $9.6M+83.5% | $7.1M+108.2% | N/A | $5.8M+51.4% | $5.3M-3.3% | $3.4M-7.1% | N/A |
| Investing Cash Flow | -$372.8M-2519.8% | -$316.7Mn/m | $42.0Mn/m | $35.0Mn/m | $15.4Mn/m | -$39.5Mn/m | -$162.5Mn/m | $0 |
| Financing Cash Flow | $11.7M+1457.3% | $762.3M+3779.2% | $5.3M+429.8% | $245.9M+6358.3% | $749K-98.9% | $19.6M+82.1% | $1.0M-99.4% | $3.8M+46.8% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
DFTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -5.3%+46.3pp | -17.3%+5.8pp | -27.7%-17.2pp | -15.2%-0.8pp | -51.5%-46.3pp | -23.1%-20.2pp | -10.5%+17.3pp | -14.4%+16.2pp |
| Return on Assets | -4.7%+23.6pp | -14.3%+1.8pp | -19.2%-10.7pp | -11.5%0.0pp | -28.4%-24.1pp | -16.1%-13.9pp | -8.5%+11.3pp | -11.5%+7.7pp |
| Current Ratio | 15.53+12.2x | 6.95+2.0x | 4.69-2.6x | 6.29-1.0x | 3.30-5.7x | 4.98-0.9x | 7.27+3.4x | 7.25+4.0x |
| Debt-to-Equity | 0.04-0.3x | 0.04-0.2x | 0.150.0x | 0.120.0x | 0.31+0.2x | 0.22+0.1x | 0.100.0x | 0.09-0.1x |
| Liabilities-to-Equity | 0.11-0.7x | 0.21-0.2x | 0.44+0.2x | 0.32+0.1x | 0.81+0.6x | 0.43+0.1x | 0.24-0.2x | 0.25-0.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Definium Therapeutics, Inc. DFTX | FY2025 | N/A | -$183.8M | N/A | $4.7B | — |
| Edgewise Therapeutics, Inc. EWTX | FY2025 | N/A | -$167.8M | N/A | $5.1B | — |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $4.0B | 49/100 |
| Erasca, Inc. ERAS | FY2025 | N/A | -$124.5M | N/A | $5.4B | — |
| Dianthus Therapeutics, Inc. DNTH | FY2025 | $2.0M | -$162.3M | N/A | $5.0B | 56/100 |
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $5.0B | 72/100 |
Where Definium Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Definium Therapeutics, Inc. (DFTX) reported a net loss of $337.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $183.8M.
As of fiscal year 2025, Definium Therapeutics, Inc. (DFTX) had $257.8M in cash and equivalents against $40.6M in long-term debt.
Definium Therapeutics, Inc. (DFTX) has a return on equity of -55.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Definium Therapeutics, Inc. (DFTX) recorded an outflow of $131.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Definium Therapeutics, Inc. (DFTX) had $440.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Definium Therapeutics, Inc. (DFTX) invested $117.7M in research and development during fiscal year 2025.
Definium Therapeutics, Inc. (DFTX) had a current ratio of 6.29 as of fiscal year 2025, which is generally considered healthy.
Definium Therapeutics, Inc. (DFTX) had a debt-to-equity ratio of 0.12 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Definium Therapeutics, Inc. (DFTX) had a liabilities-to-equity ratio of 0.32 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Definium Therapeutics, Inc. (DFTX) had a return on assets of -41.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Definium Therapeutics, Inc. (DFTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.7B as of Nov 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Definium Therapeutics, Inc. (DFTX) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.7B as of Nov 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Definium Therapeutics, Inc. (DFTX) held $411.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $131.6M over that year. Dividing the one by the other, the reported balance equals about 38 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Definium Therapeutics, Inc. (DFTX) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Definium Therapeutics, Inc. (DFTX) reported a net loss of $183.8M while operations used $131.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Definium Therapeutics, Inc. (DFTX) reported an operating loss of $166.3M against $5.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.